Bolt Accounts Payable from 2010 to 2024

BOLT Stock  USD 0.60  0.02  3.45%   
Bolt Biotherapeutics Accounts Payable yearly trend continues to be comparatively stable with very little volatility. Accounts Payable will likely drop to about 2.7 M in 2024. Accounts Payable is the amount Bolt Biotherapeutics owes to suppliers or vendors for products or services received but not yet paid for. It represents Bolt Biotherapeutics' short-term liabilities. View All Fundamentals
 
Accounts Payable  
First Reported
2019-12-31
Previous Quarter
2.6 M
Current Value
1.5 M
Quarterly Volatility
M
 
Covid
Check Bolt Biotherapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Bolt Biotherapeutics' main balance sheet or income statement drivers, such as Net Interest Income of 6.5 M, Interest Income of 6.5 M or Depreciation And Amortization of 2.5 M, as well as many indicators such as Price To Sales Ratio of 5.11, Dividend Yield of 0.0 or PTB Ratio of 0.39. Bolt financial statements analysis is a perfect complement when working with Bolt Biotherapeutics Valuation or Volatility modules.
  
Check out the analysis of Bolt Biotherapeutics Correlation against competitors.
For more information on how to buy Bolt Stock please use our How to Invest in Bolt Biotherapeutics guide.

Latest Bolt Biotherapeutics' Accounts Payable Growth Pattern

Below is the plot of the Accounts Payable of Bolt Biotherapeutics over the last few years. An accounting item on the balance sheet that represents Bolt Biotherapeutics obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Bolt Biotherapeutics are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. It is the amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities. Bolt Biotherapeutics' Accounts Payable historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Bolt Biotherapeutics' overall financial position and show how it may be relating to other accounts over time.
Accounts Payable10 Years Trend
Slightly volatile
   Accounts Payable   
       Timeline  

Bolt Accounts Payable Regression Statistics

Arithmetic Mean1,638,556
Geometric Mean1,379,061
Coefficient Of Variation64.72
Mean Deviation901,274
Median892,000
Standard Deviation1,060,516
Sample Variance1.1T
Range2.7M
R-Value0.81
Mean Square Error410B
R-Squared0.66
Significance0.0002
Slope192,873
Total Sum of Squares15.7T

Bolt Accounts Payable History

20242.7 M
2023M
20223.6 M
20213.6 M
20201.6 M
20192.1 M

About Bolt Biotherapeutics Financial Statements

Bolt Biotherapeutics shareholders use historical fundamental indicators, such as Accounts Payable, to determine how well the company is positioned to perform in the future. Although Bolt Biotherapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in Bolt Biotherapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on Bolt Biotherapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Accounts PayableM2.7 M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Bolt Stock Analysis

When running Bolt Biotherapeutics' price analysis, check to measure Bolt Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bolt Biotherapeutics is operating at the current time. Most of Bolt Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of Bolt Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bolt Biotherapeutics' price. Additionally, you may evaluate how the addition of Bolt Biotherapeutics to your portfolios can decrease your overall portfolio volatility.